Usha Martin Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: July 1, 2025, 12:15 pm

Competitors of Usha Martin Ltd

All Competitor Stocks of Usha Martin Ltd

Quarterly Result

Last Updated: May 31, 2025, 7:24 am

Below is a detailed analysis of the quarterly data for Usha Martin Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 896.00 Cr.. The value appears strong and on an upward trend. It has increased from 861.00 Cr. (Dec 2024) to 896.00 Cr., marking an increase of 35.00 Cr..
• For Expenses, as of Mar 2025, the value is 757.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 718.00 Cr. (Dec 2024) to 757.00 Cr., marking an increase of 39.00 Cr..
• For Operating Profit, as of Mar 2025, the value is 140.00 Cr.. The value appears to be declining and may need further review. It has decreased from 143.00 Cr. (Dec 2024) to 140.00 Cr., marking a decrease of 3.00 Cr..
• For OPM %, as of Mar 2025, the value is 16.00%. The value appears to be declining and may need further review. It has decreased from 17.00% (Dec 2024) to 16.00%, marking a decrease of 1.00%.
• For Other Income, as of Mar 2025, the value is 28.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Dec 2024) to 28.00 Cr., marking an increase of 19.00 Cr..
• For Interest, as of Mar 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 9.00 Cr. (Dec 2024) to 7.00 Cr., marking a decrease of 2.00 Cr..
• For Depreciation, as of Mar 2025, the value is 28.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 26.00 Cr. (Dec 2024) to 28.00 Cr., marking an increase of 2.00 Cr..
• For Profit before tax, as of Mar 2025, the value is 133.00 Cr.. The value appears strong and on an upward trend. It has increased from 118.00 Cr. (Dec 2024) to 133.00 Cr., marking an increase of 15.00 Cr..
• For Tax %, as of Mar 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Dec 2024) to 24.00%, marking an increase of 2.00%.
• For Net Profit, as of Mar 2025, the value is 101.00 Cr.. The value appears strong and on an upward trend. It has increased from 92.00 Cr. (Dec 2024) to 101.00 Cr., marking an increase of 9.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is 3.31. The value appears strong and on an upward trend. It has increased from 3.04 (Dec 2024) to 3.31, marking an increase of 0.27.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:34 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: May 13, 2025, 2:29 pm

Below is a detailed analysis of the balance sheet data for Usha Martin Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 31.00 Cr..
• For Reserves, as of Mar 2025, the value is 2,721.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,349.00 Cr. (Mar 2024) to 2,721.00 Cr., marking an increase of 372.00 Cr..
• For Borrowings, as of Mar 2025, the value is 417.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 364.00 Cr. (Mar 2024) to 417.00 Cr., marking an increase of 53.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 579.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 570.00 Cr. (Mar 2024) to 579.00 Cr., marking an increase of 9.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 3,748.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,313.00 Cr. (Mar 2024) to 3,748.00 Cr., marking an increase of 435.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,407.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,153.00 Cr. (Mar 2024) to 1,407.00 Cr., marking an increase of 254.00 Cr..
• For CWIP, as of Mar 2025, the value is 117.00 Cr.. The value appears to be declining and may need further review. It has decreased from 166.00 Cr. (Mar 2024) to 117.00 Cr., marking a decrease of 49.00 Cr..
• For Investments, as of Mar 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 56.00 Cr. (Mar 2024) to 68.00 Cr., marking an increase of 12.00 Cr..
• For Other Assets, as of Mar 2025, the value is 2,156.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,938.00 Cr. (Mar 2024) to 2,156.00 Cr., marking an increase of 218.00 Cr..
• For Total Assets, as of Mar 2025, the value is 3,748.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,313.00 Cr. (Mar 2024) to 3,748.00 Cr., marking an increase of 435.00 Cr..

Notably, the Reserves (2,721.00 Cr.) exceed the Borrowings (417.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Usha Martin Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 13.37. This value is within the healthy range. It has decreased from 13.92 (Mar 24) to 13.37, marking a decrease of 0.55.
• For Diluted EPS (Rs.), as of Mar 25, the value is 13.37. This value is within the healthy range. It has decreased from 13.92 (Mar 24) to 13.37, marking a decrease of 0.55.
• For Cash EPS (Rs.), as of Mar 25, the value is 15.94. This value is within the healthy range. It has decreased from 16.00 (Mar 24) to 15.94, marking a decrease of 0.06.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 90.17. It has increased from 78.06 (Mar 24) to 90.17, marking an increase of 12.11.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 90.17. It has increased from 78.06 (Mar 24) to 90.17, marking an increase of 12.11.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 113.83. It has increased from 105.61 (Mar 24) to 113.83, marking an increase of 8.22.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 20.85. This value is within the healthy range. It has decreased from 20.92 (Mar 24) to 20.85, marking a decrease of 0.07.
• For PBIT / Share (Rs.), as of Mar 25, the value is 17.65. This value is within the healthy range. It has decreased from 18.40 (Mar 24) to 17.65, marking a decrease of 0.75.
• For PBT / Share (Rs.), as of Mar 25, the value is 16.68. This value is within the healthy range. It has decreased from 17.59 (Mar 24) to 16.68, marking a decrease of 0.91.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 12.73. This value is within the healthy range. It has decreased from 13.48 (Mar 24) to 12.73, marking a decrease of 0.75.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 13.35. This value is within the healthy range. It has decreased from 13.88 (Mar 24) to 13.35, marking a decrease of 0.53.
• For PBDIT Margin (%), as of Mar 25, the value is 18.31. This value is within the healthy range. It has decreased from 19.80 (Mar 24) to 18.31, marking a decrease of 1.49.
• For PBIT Margin (%), as of Mar 25, the value is 15.50. This value is within the healthy range. It has decreased from 17.42 (Mar 24) to 15.50, marking a decrease of 1.92.
• For PBT Margin (%), as of Mar 25, the value is 14.65. This value is within the healthy range. It has decreased from 16.65 (Mar 24) to 14.65, marking a decrease of 2.00.
• For Net Profit Margin (%), as of Mar 25, the value is 11.18. This value exceeds the healthy maximum of 10. It has decreased from 12.76 (Mar 24) to 11.18, marking a decrease of 1.58.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.72. This value is within the healthy range. It has decreased from 13.14 (Mar 24) to 11.72, marking a decrease of 1.42.
• For Return on Networth / Equity (%), as of Mar 25, the value is 14.80. This value is below the healthy minimum of 15. It has decreased from 17.81 (Mar 24) to 14.80, marking a decrease of 3.01.
• For Return on Capital Employeed (%), as of Mar 25, the value is 17.64. This value is within the healthy range. It has decreased from 20.69 (Mar 24) to 17.64, marking a decrease of 3.05.
• For Return On Assets (%), as of Mar 25, the value is 10.86. This value is within the healthy range. It has decreased from 12.73 (Mar 24) to 10.86, marking a decrease of 1.87.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has decreased from 0.08 (Mar 24) to 0.05, marking a decrease of 0.03.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.12. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.12.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.98. It has decreased from 1.01 (Mar 24) to 0.98, marking a decrease of 0.03.
• For Current Ratio (X), as of Mar 25, the value is 2.85. This value is within the healthy range. It has decreased from 2.90 (Mar 24) to 2.85, marking a decrease of 0.05.
• For Quick Ratio (X), as of Mar 25, the value is 1.44. This value is within the healthy range. It has decreased from 1.46 (Mar 24) to 1.44, marking a decrease of 0.02.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.91. This value is below the healthy minimum of 4. It has increased from 1.83 (Mar 24) to 1.91, marking an increase of 0.08.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 17.97 (Mar 24) to 0.00, marking a decrease of 17.97.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 15.20 (Mar 24) to 0.00, marking a decrease of 15.20.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 82.03 (Mar 24) to 0.00, marking a decrease of 82.03.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 84.80 (Mar 24) to 0.00, marking a decrease of 84.80.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 21.54. This value is within the healthy range. It has decreased from 25.78 (Mar 24) to 21.54, marking a decrease of 4.24.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 14.15. This value is within the healthy range. It has decreased from 17.61 (Mar 24) to 14.15, marking a decrease of 3.46.
• For Enterprise Value (Cr.), as of Mar 25, the value is 10,337.20. It has increased from 9,856.70 (Mar 24) to 10,337.20, marking an increase of 480.50.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.98. This value is within the healthy range. It has decreased from 3.06 (Mar 24) to 2.98, marking a decrease of 0.08.
• For EV / EBITDA (X), as of Mar 25, the value is 16.24. This value exceeds the healthy maximum of 15. It has increased from 15.43 (Mar 24) to 16.24, marking an increase of 0.81.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.96. This value is within the healthy range. It has decreased from 3.01 (Mar 24) to 2.96, marking a decrease of 0.05.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 82.02 (Mar 24) to 0.00, marking a decrease of 82.02.
• For Price / BV (X), as of Mar 25, the value is 3.73. This value exceeds the healthy maximum of 3. It has decreased from 4.09 (Mar 24) to 3.73, marking a decrease of 0.36.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.96. This value is within the healthy range. It has decreased from 3.01 (Mar 24) to 2.96, marking a decrease of 0.05.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness